Inactive Instrument

News CorMedix Inc. NYSE

Stocks

US21900C1009

Pharmaceuticals

All News

Jun. 08	U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation	AQ
May. 15	Cormedix Therapeutics to Participate in two Upcoming Investor Conferences	AQ
May. 14	CorMedix Inc., Q1 2026 Earnings Call, May 14, 2026
May. 14	CorMedix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 14	CorMedix: Q1 Earnings Snapshot	AQ
May. 14	Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
May. 14	CorMedix Therapeutics Raises Earnings Guidance for the Full-Year 2026	CI
May. 05	CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026	AQ
Apr. 28	RBC Raises Price Target on CorMedix to $14 From $13, Keeps Outperform, Speculative Risk	MT
Apr. 27	CorMedix Says Rezzayo Met Primary Endpoint in Study of Prevention of Invasive Fungal Diseases	MT
Apr. 27	Cormedix Therapeutics announces positive topline results from phase III Respect trial	RE
Apr. 27	CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients	AQ
Apr. 27	Cormedix Therapeutics Announces Positive Topline Results from Phase III Respect Trial Assessing Rezzayo for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients	CI
Apr. 07	CorMedix to Participate in Needham Virtual Healthcare Conference	AQ
Mar. 05	CorMedix Inc., Q4 2025 Earnings Call, Mar 05, 2026
Mar. 05	CorMedix Shares Fall After Q4 Profit Miss	MT
Mar. 05	CorMedix Inc. Reiterates Earnings Guidance for the Year 2026	CI
Mar. 05	CorMedix Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Mar. 05	CorMedix: Q4 Earnings Snapshot	AQ
Mar. 05	CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	AQ
Mar. 02	CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026	AQ
Feb. 12	CorMedix to Participate in Upcoming Investor Conferences	AQ
Feb. 11	CorMedix's Growth Outlook Hinges on Trial Data, Prophylaxis Opportunity, RBC Says	MT
Feb. 10	CorMedix Inc. - Analyst/Investor Day
Feb. 02	CorMedix Authorizes Up to $75 Million Stock Buyback; Shares Rise	MT